Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 and anti–PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Proc Natl Acad Sci U S A
Autores principales: Wei, Spencer C., Anang, Nana-Ama A. S., Sharma, Roshan, Andrews, Miles C., Reuben, Alexandre, Levine, Jacob H., Cogdill, Alexandria P., Mancuso, James J., Wargo, Jennifer A., Pe’er, Dana, Allison, James P.
Formato: Artigo
Lenguaje:Inglês
Publicado: National Academy of Sciences 2019
Materias:
Biological Sciences
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842624/
https://ncbi.nlm.nih.gov/pubmed/31636208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1821218116
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares